Clémentine Sarkozy, Mary Bridgid Callanan, Catherine Thieblemont, Lucie Obéric, Barbara Burroni, Krimo Bouabdallah, Ghandi Damaj, Benoit Tessoulin, Vincent Ribrag, Roch Huout, Franck Morschhauser, Samuel Griolet, Clémentine Joubert, Victoria Cacheux, Vincent Delwail, Violaine Safar, Remy Gressin, Morgane Cheminant, Marie-Helene Delfau-Larue, Olivier Hermine, Elizabeth A Macintyre, Steven Le Gouill
Obinutuzumab (O) and Rituximab (R) are two CD antibodies that have never been compared in a prospective randomised trial in mantle cell lymphoma (MCL). Herein, we report the long-term outcome of the LYMA-101 (NCT02896582) trial, in which newly diagnosed MCL patients were treated with chemotherapy plus O before transplantation followed by O maintenance (O group). We then compared these patients to those treated with the same treatment design with Rituximab instead of O (R group) (NCT00921414). A propensity score matching (PSM) was used to compare the two populations (O vs R groups) in terms of MRD at the end of induction (EOI), PFS and OS...
April 26, 2024: Blood